HER-2 overexpression HER-2 overexpression	Hormone Receptor Negative Breast Cancer Hormone Receptor Negative Breast Cancer	trastuzumab + lapatinib Sensitive: A1 - Approval
HR negative HR negative	Hormone Receptor Negative Breast Cancer Hormone Receptor Negative Breast Cancer	TCHP Sensitive: C3 – Early Trials
HER-2 amplification + HER-2 R157W HER-2 amplification + HER-2 R157W	Hormone Receptor Negative Breast Cancer Hormone Receptor Negative Breast Cancer	pyrotinib Sensitive: C4 – Case Studies

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

Hormone Receptor Negative Breast Cancer

Associations(3)